FDA denial could delay launch of Minerva’s schizophrenia treatment roluperidone by at least two years: GlobalData Read more
FOPE request govt for funding to MSME to upgrade manufacturing facilities for revised Schedule M Read more
Takeda oncology pipeline remains robust despite shift in focus from CAR-T to allogeneic cell therapies: GlobalData Read more